Zeltherva
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Zeltherva’s (galinpepimut-S; SELLAS Life Sciences Group) larger target patient population gives it more commercial potential than other drugs being positioned towards the maintenance setting. Its biggest competition comes from oral Vidaza (azacitidine; Celgene), which is also in development for the maintenance treatment of elderly patients in complete remission regardless of mutation status, and is significantly ahead of Zeltherva in development.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 Zeltherva : Acute myeloid leukemia (AML)
LIST OF FIGURES
8 Figure 1: Zeltherva for acute myeloid leukemia – SWOT analysis
9 Figure 2: Datamonitor Healthcare’s drug assessment summary of Zeltherva for acute myeloid leukemia
10 Figure 3: Datamonitor Healthcare’s drug assessment summary of Zeltherva for acute myeloid leukemia
LIST OF TABLES
5 Table 1: Zeltherva drug profile
7 Table 2: Zeltherva Phase II data
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Gilteritinib 
Sign up to the